NASDAQ:NVAX - Novavax Stock Price, Forecast & News

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Novavax's stock reverse split before market open on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 9th 2019. An investor that had 100 shares of Novavax stock prior to the reverse split would have 5 shares after the split.

Novavax, Inc. (NASDAQ:NVAX) released its earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.98) by $0.24. The biopharmaceutical company earned $2.51 million during the quarter, compared to analysts' expectations of $4.40 million. During the same quarter in the previous year, the firm earned ($2.40) earnings per share. View Novavax's Earnings History.

Novavax is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Novavax.

9 analysts have issued twelve-month price targets for Novavax's stock. Their forecasts range from $7.00 to $27.50. On average, they anticipate Novavax's share price to reach $15.93 in the next year. This suggests a possible upside of 113.7% from the stock's current price. View Analyst Price Targets for Novavax.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 2 sell ratings, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novavax.

Media stories about NVAX stock have trended positive this week, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Novavax earned a media sentiment score of 2.6 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Novavax.

Some companies that are related to Novavax include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Egalet (EGLT), EXACT Sciences (EXAS), Palo Alto Networks (PANW), Akebia Therapeutics (AKBA), TG Therapeutics (TGTX), Cara Therapeutics (CARA), Trevena (TRVN), Gilead Sciences (GILD), Ocular Therapeutix (OCUL) and 22nd Century Group (XXII).

Novavax's stock is owned by many different of institutional and retail investors. Top institutional investors include TSP Capital Management Group LLC (0.39%). Company insiders that own Novavax stock include Gregory M Glenn, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rachel K King and Stanley C Erck. View Institutional Ownership Trends for Novavax.

NVAX stock was purchased by a variety of institutional investors in the last quarter, including TSP Capital Management Group LLC. Company insiders that have bought Novavax stock in the last two years include Gregory M Glenn, John Trizzino, Rachel K King and Stanley C Erck. View Insider Buying and Selling for Novavax.

Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVAX stock can currently be purchased for approximately $7.46.

Novavax has a market capitalization of $239.45 million and generates $34.29 million in revenue each year. The biopharmaceutical company earns $-184,750,000.00 in net income (profit) each year or ($10.00) on an earnings per share basis. Novavax employs 373 workers across the globe.View Additional Information About Novavax.

The official website for Novavax is http://www.novavax.com/.

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at 240-268-2000 or via email at [email protected]